Gilead’s unique $5.1 billion licensing deal shows the range of IP monetisation options open to biotech sector
New boss explains that the Big Pharma company will seek out “diverse and creative” asset partnerships – rather than large acquisitions – to boost its pipeline
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.